Masters Programme Endorsed by Leading Multinational Top 20 Pharmaceutical Companies Through the Asia Training Consortium
ClinTec International and Edinburgh Napier University are delighted to announce that the Asia Training Consortium has endorsed the Masters in International Clinical Research and Technology for clinical research professionals.
The Asia Training Consortium (ATC) was founded in 2012 as a unified platform for pharmaceutical companies to establish common goals and share resources to provide world-class training and development in clinical research in Asia. It is currently a consortium of 17 companies, including large top 20 pharmaceutical companies such as Merck, Novartis, Pfizer, Astellas and AstraZeneca, global CROs and training institutions including Edinburgh Napier University. This is the first endorsement from ATC of an academic qualification to meet the needs for further qualifications for research professionals.
The Masters in International Clinical Research and Technology was launched last year between Edinburgh Napier University and ClinTec International to support the development of clinical research staff throughout the world and has now been endorsed by the ATC. This innovative Masters programme is an exciting collaboration, which builds upon the clinical research and educational expertise that exists within these two organisations. The Masters programme is accessible globally and has enrolled students from 14 countries, including students based in UAE, Lebanon, South Africa, India and the Philippines, as well as from France, Austria, Sweden, UK, Czech Republic, Slovenia, Lithuania, Croatia and Romania. This successful innovative industry/academic collaboration leading to a Masters Degree led to ClinTec being awarded the Microsoft Innovation of the Year Award 2014 at the UK’s largest Business Award Ceremony, with guest speaker global entrepreneur, Sir Richard Branson. Over the last 5 years, ClinTec and Edinburgh Napier University have delivered clinical research courses to over 1000 clinical professionals globally, with over 200 based in Asia.
ClinTec International is a global CRO, with a presence in over 50 countries across 5 continents. On the occasion of the endorsement of the Masters programme by ATC, Dr Rabinder Buttar, Founder, Chairman and CEO of ClinTec International, commented: “ClinTec International is delighted to receive this endorsement from the Asia Training Consortium. As ClinTec has a global presence in over 50 countries, we are very pleased to be associated with a platform that provides world-class training and development in Asia”.
Professor Andrea Nolan, Principal and Vice-Chancellor of Edinburgh Napier University stated: “At Edinburgh Napier University we have a history of collaborating with industry to give students the best possible education to equip them to become leaders in their field. We are delighted to have the endorsement from the Asia Training Consortium who share the joint aspirations of providing world class training for clinical research professionals”.
John Constantine, Chair, Asia Training Consortium, said: “This is yet another example of collaboration within and across industries to further quality and excellence in clinical research. ATC membership is excited to have this endorsement between a respected University, Edinburgh Napier University, and ClinTec, one of the premier contract research organizations. I look forward to further collaborations like this between ATC members in the future.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...